Because Notch is a breast oncogene that is critical for survival and proliferation of breast cancer cells, our findings strongly suggest that combined treatment with a Notch inhibitor should be an effective therapeutic strategy to prevent tumour recurrence and possibly disease progression and death in ErbB-2-positive breast cancer. Here, ERBB2 is linked to neoplasm.